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Abstract
Heavy menstrual bleeding (HMB) is often undiagnosed in women and can cause discomfort
and distress. A haemostatic cause for excessive bleeding is often not routinely investigated and
can lead to hysterectomy at an early age. A prospective cohort study was carried out to
determine whether certain patients with unexplained HMB have an underlying platelet func-
tion defect (PFD). The Genotyping and Phenotyping of Platelets (GAPP) study recruited 175
women with HMB and 44 unrelated volunteers from 25 Haemophilia Centres across the UK,
and a tertiary gynaecology service. Bleeding history was assessed using the International
Society on Thrombosis and Haemostasis Bleeding Assessment Tool (ISTH-BAT). Platelet count,
platelet size, haemoglobin and mean corpuscular volume were measured in whole blood using
the Sysmex XN-1000 Haematology Analyzer. Platelet function testing using lumiaggregometry
and flow cytometry was performed in patients included in this study. A PFD was identified in
47% (82/175) of patients with HMB. Cutaneous bleeding was the most frequent additional
bleeding symptom (89% in PFD and 83% with no PFD). Whole blood platelet count was
significantly lower (P < 0.0001) between the PFD group and no PFD group. The prevalence
of anaemia did not differ between patients and healthy volunteers. Clinical evaluation alone is
insufficient to determine presence of an underlying PFD in patients with HMB. Platelet function
tests may be considered and clinical guidelines may include them in their algorithms. An
appropriate diagnosis and subsequent tailored management of HMB may prevent unnecessary
surgery and help manage future haemostatic challenges.
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Introduction
Heavy menstrual bleeding (HMB) has been quantitatively defined
as menstrual bleeding exceeding seven days or a blood loss of
more than 80 millilitres per cycle. However, such a definition is
not useful clinically and does not take into account the impact of
HMB on the individual. A more contemporary definition is that
proposed by the National Institute of Health and Care Excellence
(NICE): “excessive menstrual blood loss which interferes with
a woman’s physical, social, emotional and/or material quality of
life” [1]. HMB is common in women of reproductive age [2]
accounting for a large proportion of health care resources in
primary and secondary care [3]. Internationally, the World
Health Organisation estimates that 18 million women suffer
from HMB [4].
There are a variety of medical, radiological and surgical
treatments for HMB but accurate diagnosis of the underlying
cause is needed to optimise outcomes [3]. Several structural
and non-structural causes for HMB have been identified within
the International Federation for Obstetrics and Gynaecology
(FIGO) PALM-COEIN classification system. Systemic disor-
ders of haemostasis are recognised as a cause of HMB [5].
From a haematological perspective, the 2018 NICE HMB
guideline update [6] recommends assessment of anaemia
through the taking of a full blood count (FBC) but laboratory
testing for coagulopathies such as von Willebrand’s Disease
(VWD) is only recommended in selected cases, namely
women who have had HMB since menarche or have
a personal or family history suggesting a coagulation disorder.
However, in general gynaecological practice systematic screen-
ing for potential bleeding disorders through structured history
taking is not routine. Thus, the prevalence of mild bleeding
disorders (MBDs) contributing to HMB may be underestimated
and women may receive suboptimal or unnecessary treatment
impacting adversely upon their quality of life.
Color versions of one or more of the figures in the article can be found
online at www.tandfonline.com/iplt.
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Research suggests that women with PFD or coagulation
defects, e.g. VWD, experience severe bleeding problems
including HMB [7]. An estimated 13–20% of women with
unexplained HMB have reduced VWD levels [8]. However,
the frequency of other potential underlying bleeding disorders
and mild platelet disorders have not been confirmed [9].
Currently, there are no guidelines addressing platelet function
testing in patients with HMB [7,10]. Recent studies have sug-
gested that investigation of an underlying platelet defect in
females with unexplained HMB can optimise management
and reduce rates of surgical intervention such as hysterectomy
in affected women [7,10]. Thus, comprehensive diagnosis of
the underlying causes of HMB, including the presence of
MBDs, can optimise patient outcomes by avoiding ineffective
treatments, and preventing unnecessary surgery such as hyster-
ectomy with its associated morbidity and costs. Medical treat-
ments can then be targeted at the underlying haematological
problem which may be contributing wholly or partly to the
HMB. Therapies such as inhibitors of fibrinolysis (e.g. tranexa-
mic acid), desmopressin or platelet transfusions could be
considered.
The UK-GAPP study began in 2006 when the goal was to
perform functional and genetic studies on patients with clinically
diagnosed platelet-based bleeding disorders of unknown cause. It
has recruited over 850 patients from 25 collaborating
Haemophilia Centres and from a tertiary gynaecology service
[11]. A proportion of the female participants have unexplained
HMB and may have undiagnosed platelet function defects (PFD)
which account for their symptoms. This study aimed to analyse
the data of patients with HMB within the GAPP study to deter-
mine whether a significant proportion of patients with HMB have
a previously undiagnosed PFD.
Methods
Population
Women were recruited from participating UK Haemophilia
Centres and a specialist gynaecology service at the Birmingham
Women’s Hospital. Women were eligible to participate in the
GAPP study (2006–2017) if they were: aged 16 years or older;
referred to secondary care with the possibility of an underlying
bleeding disorder based on their clinical history and were willing
to take part in the study and were capable of providing informed
consent. Women with HMB who had no uterine structural
abnormalities (e.g. fibroids or polyps on pelvic ultrasound) pre-
senting to a specialist gynaecology service were also invited to
participate. Women were excluded if they had: no history of
HMB; taken drugs which could influence platelet function within
seven days of enrolment; been previously diagnosed with
a bleeding disorder such as VWD; undergone major surgery in
the last 6 months; chronic renal failure needing dialysis; a platelet
count outside the range 100 000–450 000/μL; severe anaemia
(haemoglobin (Hb) <80 g/L). In order to establish standardised
reference ranges for laboratory parameters of platelet function,
blood was taken from a group of consenting healthy volunteers to
act as controls.
The UK-GAPP study was approved by the National
Research Ethics Service Committee of West Midlands –
Edgbaston (06/MRE07/36) and participants gave written
informed consent in accordance with the Declaration of
Helsinki. The GAPP study was registered at www.isrctn.org
as #ISRCTN 77951167 and is included in the National
Institute of Health Research Non-Malignant Haematology
study portfolio, (ID-9858).
ISTH BAT
The International Society on Thrombosis and Haemostasis
Bleeding Assessment Tool (ISTH-BAT) was used to provide an
objective evaluation of the patients bleeding history. This score
was developed in an attempt to standardise history taking in
patients with excessive bleeding. A score of 4 or over is consid-
ered to be elevated [12]. The ISTH bleeding scores were gener-
ated by an experienced clinician before platelet function tests
were performed to avoid biased interpretation of the bleeding
history following lumiaggregometry [13]. Further studies were
performed to assess the platelet defects and their severity. The
patients with platelet function defects were grouped based on the
type of platelet defect detected by lumiaggregometry and their
ISTH-BAT scores were compared.
Blood Cell and Platelet Counts and Morphology
Bleeding severity is related to platelet count and platelet func-
tion. Therefore, platelet counts and morphology were measured
from patients in whole blood using the Sysmex XN-1000
Haematology Analyzer (n = 103) (Sysmex, Milton Keynes,
UK) and other methods. The PLT-F channel was used to deter-
mine platelet counts in whole blood. The haemoglobin (Hb)
concentration, mean corpuscular volume (MCV) and mean pla-
telet volume (MPV) were measured and compared between the
groups. MPV, a machine-calculated measurement of the average
size of platelets found in blood, tends to correlate with platelet
function and is a good marker of platelet activation and reactiv-
ity [14,15], was determined from the impedance PLT-I channel.
All samples were processed in tandem with travel controls,
which are taken from healthy volunteers and transported and
tested at the same time as participants. In addition to the mea-
surement of Hb to indicate anaemia the MCV was also tested to
give the average volume of red cells. Instrument performance
was ensured by the use of daily internal quality controls (XN
check, Sysmex, Milton Keynes, UK) and monthly external qual-
ity controls (UKNEQAS, Watford, UK).
Platelet Preparation and Platelet Function Testing
Previous studies by the UK-GAPP study group have demonstrated
the applicability of using light transmission aggregometry (LTA),
including lumiaggregometry for testing patients with a suspected
PFD to account for their bleeding symptoms [11,13,16,17].
Lumiaggregometry was used to simultaneously test platelet
aggregation and secretion, for investigation of Platelet Rich
Plasma (PRP) samples having platelet counts exceeding
1 × 108/mL and an in-house flow-cytometry assay to assess
platelet function in patients having platelet counts in PRP of
less than 1 × 108/mL as LTA is not reliable for low platelet
counts [16]. The patients tested were found have a platelet defect
using a rationalised platelet agonist panel (as outlined in Dawood
et al. 2012 and Tables I and 2) choosing dose points from
previous work on healthy volunteers in the GAPP study
[13,16,17]. To consider the frequency of any abnormal results/
platelet responses in the healthy control population we performed
platelet aggregation and secretion in 68 healthy volunteers
(Supplementary figure 1). The higher concentrations of agonists
resulted in narrow reference intervals, but lower agonist concen-
trations (including some routinely used in current laboratory
practice, such as ADP 3 µM and collagen 1 µg/mL) were sig-
nificantly more variable.
In diagnosing whether the patient had a platelet function dis-
order, we made a judgment on their clinical bleeding history in
combination with their platelet responses patterns. These are
based on the higher agonist doses used in terms of their maximal
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amplitude and temporal response patterns for each agonist.
A demonstrable platelet defect was observed in patients with
abnormal aggregation and/or secretion responses and defects
mostly fell into the categories of dense granule secretion defect,
Gi pathway signalling defect and cyclooxygenase pathway
defects. The platelet granule secretion was tested by assessment
of the ATP-secretion levels in the PRP using a luciferase assay as
previously described [13]. All blood tests and assays were per-
formed within 4 hours of blood collection as previously studied
[17]. Furthermore, the effect of distance travelled for transporting
samples over 100 miles was not found to alter platelet aggregation
responses (Supplementary Figure 2).
Statistical Methods
Scatter dot plots were constructed to show the spread of data
within each patient group with horizontal bars indicating the
median and interquartile ranges. Statistical analysis between
groups was performed using parametric unpaired t-tests for nor-
mally distributed data. Where multiple comparisons between the
mean of each groups with others, a parametric ordinary one-way
ANOVA with Tukey multiple comparisons test was used. For
non-normally distributed data, a non-parametric Kruskal-Wallis
test was used to compare means and Dunn’s adjustment applied
for multiple comparisons to compare the mean rank of each group
with the mean rank of every other group. An ordinary two-way
ANOVA with Sidak’s multiple comparisons test was used to
compare between the patient groups with and without a platelet
defect.
Results
A total of 175 women with a history of HMB as a primary
bleeding complaint and 44 unrelated healthy volunteers were
analysed in this study (Figure 1).The median age of the recruited
patients with HMB was 42 years and the interquartile range (IQR)
was 32 to 51 years. Over a quarter of the patients were in the age
range of 41–50 (27%) followed by: over 50 years (26%), 31–-
40 years (25%), 20–30 years (16%) and less than 20 years (5%).
The healthy volunteers forming the control group were younger
with a median age of 32 years and the IQR was 22 to 36.5.
Identification of Patients with Bleeding History and Platelet
Defects Using ISTH-BAT and Lumiaggregometry
All women had a bleeding history taken at the point of inclusion
into the study. In addition to HMB, most patients suffered from
a variety of bleeding symptoms including epistaxis, cutaneous
bruising, bleeding from minor wounds, haematuria, gastrointest-
inal bleeding, oral cavity bleeding, bleeding after tooth extraction,
surgery, major trauma or child birth (Table III). ISTH-BAT scores
were available in all 175 women with HMB and for 22/44 (50%)
of the healthy controls. Lumiaggregometry identified platelet
defects in 82/175 (47%) women (Table III). Statistical analysis
performed using two-way ANOVA with Sidak multiple compar-
isons test showed no significant difference (p > 0.05) in any of
the bleeding symptoms between the patient groups with and with-
out a platelet defect.
Systemic Bleeding Severity, Heavy Menstrual Bleeding and
Platelet Defects
The ISTH-BAT scores were compared amongst the control, no
platelet defect and platelet defect groups in order to assess
whether the severity of bleeding varied between women with
and without HMB and between women with HMB according to
the presence of a platelet defect (Figure 2). The median ISTH-
BAT score for the control group was 0 indicating no bleeding
symptoms and the 95th percentile was 4.9. The median overall
score for the HMB group was 12 (IQR 8–16), which was sig-
nificantly higher than the control women without HMB
(P = < 0.0001). The median ISTH-BAT scores did not differ
Table I. The streamlined panel of agonists used for lumi-
aggregometry in diagnosing platelet function defects in 175 women
with HMB. ATP secretion from dense granules was measured with ADP
30 µM, adrenaline 10 µM, arachidonic acid 1 mM, PAR1 – specific
peptide 100 µM and collagen 3 µg/ml.
Agonist Concentration Comments/further guidance
ADP 10 µM Maximal, sustained aggregation
expected at this concentration. If
reversible aggregation seen use
30 µM.
Adrenaline 10 µM Biphasic aggregation expected. If
aggregation absent or reduced use
30 µM.
Arachidonic acid 1 mM Maximal, sustained aggregation
expected. If aggregation reduced
or reversible use U46619 3 µM.
PAR-1 receptor
specific peptide
(SFLLRN)
100 µM Maximal, sustained aggregation
expected. If aggregation reduced
use PAR-4 receptor specific
peptide (AYPGKF; 500 µM).
Collagen 1 µg/ml If aggregation reduced use 3 µg/
ml. If this concentration shows
reduced aggregation, use collagen
related peptide (CRP) 3 µg/ml.
Ristocetin 1.5 mg/ml Maximal, sustained agglutination
(often biphasic) expected. If
reduced consider vWF profile and
GPIb levels by flow cytometry.
Table II. Typical lumi-aggregometry findings in the commonly encoun-
tered platelet defects within the HMB cohort.
Platelet defect Aggregation results Secretion results
Secretion
defects
Absence of secondary wave
aggregation to most agonists
used in low concentrations,
and epinephrine at all
concentrations
Significantly reduced
levels of ATP secretion
(when normalized for
platelet count)
Thromboxane
pathway
defects
Absence/severe reduction of
aggregation in response to
arachidonic acid while
response to thromboxane
mimetics is preserved (for
cyclooxygenase defects) or
absence of aggregation
response to both arachidonic
acid and thromboxane
mimetics (for thromboxane
receptor defects)
Commonly, absence of
secondary wave aggregation
to most agonists used in low
concentrations, and
epinephrine at all
concentrations
Normal
Gi-coupled
receptor
defects
Reduced aggregation to
ADP with notable
deaggregation even at high
concentrations of agonist
Reduced primary wave
response to epinephrine and
absence of secondary wave
Normal
DOI: https://doi.org/10.1080/09537104.2018.1543865 Platelet Defects in Women with HMB 3
significantly between those HMB women according to the pre-
sence of a detectable platelet defect; the HMB platelet defect
group was 13 (IQR 8 to 17) compared to a median ISTH-BAT
score for the HMB no defect group of 11 (IQR 8 to 15)
(P = 0.46). Similarly, no differences between women with or
without platelet defects were observed when the ISTH-BAT
score calculation was restricted to the severity of bleeding in
relation to menstruation (i.e. HMB alone) (median HMB score
3, IQR 2 to 4 vs. median HMB score 3, IQR of 2 to 4,
respectively).
In the 82 women where platelet function defects were detected
by lumiaggregometry, the type of platelet defect was sub-grouped
into six distinct categories; cyclo-oxygenase deficiency (10%), Gi
receptor signalling defect (20%), secretion defect (18%), throm-
bocytopenia (30%), ADP P2Y12 receptor defect (4%) and “other”
defects (18%). The latter group of women with HMB had abnor-
mal lumiaggregometry but without a clearly identified platelet
defect. The association between the systemic bleeding severity as
estimated by the ISTH-BAT scores was then compared according
to the type of platelet defect (Figure 3). The groups of patients
identified by lumiaggregomtery are also shown independent of
the BAT score (Figure 4). The ISTH-BAT scores were not avail-
able for three patients.
The most common finding was thrombocytopenia
(100–150 × 109/L), which was found in 14% (n = 24/175) of
HMB patients. Of the specific platelet function defects detected,
women with thrombocytopenia had the lowest median ISTH-BAT
score = 10 (IQR 8 to 13.5) along with platelet secretion defects
(median ISTH-BAT score = 10, IQR 6.5 to 17). An ADP receptor
defect was the least commonly detected defect, seen in 2% (n = 3/
175) of all women with HMB but the anomaly was associated
with highest median ISTH-BAT score = 17 (IQR 6 to 18). The
8% (n = 13) of women with abnormal lumiaggregometry fell into
the “other” category, which contained women without a clearly
identified platelet defect; the median ISTH-BAT in this group was
10 and the IQR was 8 to 17 (Figure 3).
Other Laboratory Findings
Additional parameters were measured in each patient’s blood
samples to further determine the possibility of an underlying
platelet function defect. As bleeding severity is related to platelet
count and platelet function whole blood platelet counts using
PLT-F are shown for all recruited patients (Figure 5). The mean
for the healthy control group of women without HMB was not
significantly lower at 213.1 × 109/L compared to the mean of all
Figure 1. Spread of ages for all recruited patients.A scatter dot plot showing the spread of ages of all recruited patients in this study. The patients age
was available for 22 healthy controls and 154 HMB patients. Horizontal bars indicate median and interquartile range. Statistical analysis was performed
using parametric unpaired t-test, statistically significant difference is denoted by **** P < 0.0001.
Table III. Phenotypic symptoms of 175 patients recruited to the UK-
GAPP study with HMB of unknown aetiology. Types of bleeding
symptoms were assessed using the ISTH-BAT and the percentage of
patients suffering from a platelet defect or no platelet defect using lumi-
aggregometry are listed. Statistical analysis was performed using ordinary
two-way ANOVA with Sidak’s multiple comparisons test. P-values are
listed, no statistical significance was noted (P ≥ 0.05).
Type of bleeding
Patients
with
platelet
defect
(n = 82)
Patients
with no
platelet
defect
(n = 93)
Percentage of total
patients with
bleeding
tendencies P-value
Heavy menstrual
bleeding
82 93 100 0.9898
Cutaneous
bleeding
73 77 85.7 >0.9999
Oral cavity
bleeding
66 69 77.1 >0.9999
Bleeding from
minor wounds
55 57 64.0 >0.9999
Bleeding after
tooth/teeth
extraction
55 48 58.9 >0.9999
Epistaxis 48 45 53.1 >0.9999
Post-partum
hemorrhage
38 45 47.4 0.9998
Bleeding after
surgery/major
Trauma
44 33 44 0.9898
Gastrointestinal
bleeding
25 28 30.3 >0.9999
Hematuria 18 25 24.6 0.9998
Muscle
hematomas or
hemarthrosis
(spontaneous)
14 10 13.7 >0.9999
Other bleeding1 66 38 59.4 0.2343
1other bleeding episodes includes: venipuncture and ovulation bleeding,
conjunctival hemorrhage or excessive bleeding following or venipunc-
ture. Overall some patients had > 1 other bleeding complaint
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women reporting HMB, which was 237.5 × 109/L, P = 0.1943).
In women with HMB and no platelet defect identified by lumiag-
gregometry, the mean PLT-F was significantly higher at
262.8 × 109/L compared to 201 × 109/L in HMB women with
a platelet defect (P < 0.001).
The observed differences in PLT-F between women with and
without HMB and those HMB affected women with and without
platelet defects could not be explained by the presence of anae-
mia. The median haemoglobin (Hb) level for the control group of
women without HMB was 134 g/L (IQR 125 to 142 g/L) and
136 g/L (IQR 127 to 141g/L) in women with HMB (Figure 6a).
The median Hb did not differ between women with HMB accord-
ing to the presence or absence of a platelet defect (135 g/L, IQR
of 126 to 142 g/L vs. 137 g/L, IQR of 129 to 141 g/L. In the
absence of anaemia, red blood size was tested and found to be
within normal limits. Analysis of the mean cell volume (MCV) in
the different groups showed no differences between women with
and without HMB (87.3fL, IQR 84.5 to 92fL vs. 90.0fL, IQR
87.0 to 92.6 fL; P = 0.3427)) and women with HMB according to
the presence or absence of a platelet function defect (90.4 fL, IQR
87.3 to 93.6 fL vs. 89.7 fL, IQR 86.9 to 92 fL respectively;
P > 0.05) (Figure 6b).
Mean platelet Volume
The median MPV was significantly lower in women with HMB
compared to those women without HMB (healthy controls) (10.5
fL, IQR of 9.3 to 11.7 fL vs. 11.4 fL, IQR 10.5 to 12 fL
respectively; P = 0.0199) (Figure 6c). No differences in MPV
were seen in women with and without detectable platelet defects
10.5 fL, IQR of 8.9 to 11.9 fL1vs. 0.6 fL, IQR 9.3 to 11.63 fL,
respectively. The median MPV of the platelet defect group was
10.5 fL with an IQR of 8.9 to 11.9 fL. A significant decrease
(P < 0.05) in MPV levels were seen in all patients with HMB and
no platelet defect in comparison to controls (Figure 6c).
Other Platelet Investigations
Further assessments of platelet function were tested. The imma-
ture platelet fraction for all recruited women fell within the
normal healthy range and no significant differences were
observed between women with and without HMB or women
with HMB and a platelet function defect or not. The median
value of platelet ATP-secretion (a marker of platelet activation)
in the healthy control group was 0.925 nmol ATP/1 × 108 plate-
lets (IQR 0.75 to 1.243 nmol ATP/1 × 108 platelets), which was
not significantly different from the median ATP secretion in
women with HMB which was 0.97 nmol ATP/1 × 108 platelets
(IQR 0.7 to 1.29 nmol ATP/1 × 108 platelets) (Figure 6d). In
contrast, a significant difference in median ATP-secretion levels
was apparent between women with HMB and a platelet defect
(0.77 nmol ATP/1 × 108 platelets, IQR was 0.49 to 1.14 nmol
ATP/1 × 108 platelets) and those women with HMB and no
platelet defect (1.04 nmol ATP/1 × 108 platelets, IQR 0.85 to
1.3 nmol ATP/1 × 108); P < 0.001.
Discussion
Main Findings
This is one of the few studies to consider a large population of
patients with unexplained HMB with a previously undiagnosed
platelet function defect (PFD). We demonstrated that 47% of
women reporting HMB had an underlying PFD. The ISTH-BAT
found no differences in bleeding symptoms precluding the ability
to clinically discriminate between women with HMB who have,
or do not have, a platelet defect. Furthermore, no differences were
observed in the severity of bleeding between the “no platelet
defect” and “platelet defect” groups. The absence of anaemia is
not surprising, however, because significant iron deficiency anae-
mia is uncommon in women with HMB in the developed world in
the absence of uterine pathology such as fibroids [18]. It is also
possible that women had received treatment for iron deficiency.
Figure 2. The relationship between presence of a platelet function defect detected by lumiaggregometry and the ISTH-BAT score.A scatter dot plot
showing the spread of ISTH-BAT scores in the healthy controls (n = 22), no platelet defect (n = 89) and platelet defect (n = 82) groups. Horizontal
bars indicate median and interquartile range. Statistical analysis was performed using the non-parametric Kruskal-Wallis test and Dunn’s adjustment for
multiple comparisons, the mean rank of each column was compared with the mean rank of every other column. Statistically significant difference is
denoted by **** = P < 0.0001. No statistical significance (P = 0.46) was seen between the no platelet defect and platelet defect group.
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The most common additional bleeding symptoms in women com-
plaining of HMB were cutaneous bleeding and bleeding from
minor wounds in keeping with the findings from previous pub-
lications [19].
Strengths and Limitations
Several studies have studied the prevalence of von Willebrand’s
disease in association with HMB [8,20] but few studies have
systematically investigated PFD in women presenting with HMB
and their relative clinical impact on HMB and generalised bleed-
ing complaints. Furthermore, in contrast to previous studies [12],
the ISTH-BAT score for HMB in isolation was assessed in addi-
tion to the total ISTH-BAT score, to determine the severity of
HMB. Regardless of the presence of a PFD, the median ISTH-
BAT score for the HMB category was 3 out of 4. A score of 3
indicates that the bleeding symptoms are severe, involving the
potential need for iron therapy, time off work or school and the
potential requirement to combine treatments with antifibrinolytics
and hormonal therapy, aimed to reduce the menstrual flow. Phillip
Figure 3. The relationship between the type of platelet defect identified by lumiaggregometry and the ISTH-BAT score.A scatter dot plot showing the
spread of ISTH-BAT scores between the platelet defects identified on lumiaggregometry, healthy controls (n = 21), No defect (n = 88), defect (n = 75)
of which; cyclooxygenase defect (n = 7), Gi receptor signalling defect (Gi defect) (n = 14), Secretion defect (n = 13), thrombocytopenia (n = 25), ADP
receptor defect (n = 3) and other (n = 13). Horizontal bars indicate median and interquartile range. Statistical analysis was performed using non-
parametric Kruskal-Wallis and Dunn’s multiple comparisons test, the mean rank of each column was compared with the mean rank of every other
column. Statistically significant difference is denoted by * = P < 0.05, **** = P < 0.0001, no statistically significant difference (P > 0.05) was
observed between the platelet defect subgroups.
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et al. suggested that annually 5% of women of reproductive age
seek medical attention for their HMB, however, given the severity
of HMB identified in this study the figure is likely to be much
higher [21].
The cohort of patients assessed in this study is a hospital-based
population instead of patients recruited from primary care such
that most of the patients have already been treated for anaemia
and their bleeding is partially managed which could affect the rate
of suspected PFD. The impact of HMB and PFDs on iron defi-
ciency may have been underestimated in our study because ferri-
tin levels to assess iron stores were not evaluated. Furthermore,
the observed frequency of abnormal platelet test results may be
biased by the recruitment of subjects from haemophilia centres
and may not necessarily reflect the general population of women
with HMB. The ISTH-BAT scores were only available for 50% of
all the healthy volunteers. The group where the BAT question-
naire was taken was done on local volunteers whereas the remain-
ing controls were taken from remote sites where routine BAT
scores are not taken.
The characteristics of platelet function disorders remain
unclear and it is commonly assumed that VWD is one of the
most common bleeding disorders amongst HMB patients. The
patients were recruited to the GAPP study from hemophilia
centres and a tertiary gynaecology service on the basis that they
did not have VWD as stated in the exclusion criteria, therefore,
VWD parameters were not re-tested in this study. This is
a potential weakness given the high prevalence of VWD amongst
HMB suffers. Furthermore the accuracy and precision of the
platelet function tests are uncertain. Platelet function defects
may have been undetected by lumiaggregometry if the recognised
Figure 4. The type of platelet defect identified in the HMB group as defined by lumiaggregometry.
Figure 5. Comparison of PLT-F between types of platelet defect groups identified by lumiaggregometry. A scatter dot plot showing the spread of PLT-F
results between the recruited patients. Healthy controls (n = 43), all HMB patients (n = 103), No defect (n = 61), and defect (n = 42). Error bars
represent mean ± 1 SD. Statistical analysis was performed using parametric ordinary one-way ANOVAwith Tukey multiple comparisons test, the mean
rank of each column was compared with the mean rank of every other column. Statistically significant difference is denoted by * = P ≤ 0.05, *** = P ≤
0.001.
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type of defect was below the sensitivity levels of the tests used. It
is well known that a proportion of patients with secretion defects
have normal LTA. In order to overcome the limitation of using
LTA alone, LTA was combined with the assessment of ATP-
secretion in the method of lumiaggregometry. In addition, PFDs
may have been present that we did not test for, such as defective
procoagulant activity, disorders such as these require highly spe-
cialist testing beyond the scope of this study. Alternatively, they
could have a defect in another part of the coagulation pathway
such as fibrinolytic defects. In light of the bleeding history of
these patients, a comprehensive evaluation of potential abnorm-
alities in the entire haemostatic pathway should be performed
when technically and practically feasible.
Interpretation
The clinical assessment, laboratory evaluation and clinical man-
agement of suspected PFD amongst HMB patients is challenging.
It has been suggested that as little as 8% of women with bleeding
abnormalities undergo haemostatic evaluation [21] and that 47%
to 69% of patients with MBDs will remain undiagnosed [22].
Heavy menstrual bleeding is common and our study shows that
nearly half of women with this complaint who do not have VWD
may have a PFD. Thus, it is important to make gynaecologists
aware of PFDs as a potential contributory cause of unexplained
HMB. There is an increasing recognition that accurate diagnosis
of the underlying cause of HMB is essential to tailor treatment
and optimise clinical outcomes [5,6]. Therefore, where a woman
presents with HMB and a MBD, such as Type I VWD or
a suspected platelet function anomaly, referral to
a haematologist or specialist joint gynaecological-haematology
clinic should be considered for further management. In such
patients, if VWD or an identifiable platelet defect is not present
it is also important to consider further defects in other parts of the
haemostatic pathway such as fibrinolysis, collagen exposure and
vessel wall function, which are not routinely investigated even in
Figure 6. Other haematological and platelet function testing findings between the groups of patients in the study. (A) Comparison of haemoglobin
between healthy volunteers and recruited patients with and without a platelet defect. A scatter dot plot showing the spread of Hb results between the
recruits. Healthy controls (n = 43), all HMB patients (n = 92), no defect (n = 56), and defect (n = 36). Horizontal bars indicate median and
interquartile range. Statistical analysis was performed using non-parametric Kruskal-Wallis and Dunn’s multiple comparisons test, the mean rank of
each column was compared with the mean rank of every other column. Comparison between pairs of groups was not significant (P >0.05) for all
data points. (B) Comparison of MCV parameters between the healthy control and recruited patients with and without a platelet defect. A scatter dot
plot showing the spread of MCV results between the recruits. Healthy controls (n = 42), all recruited HMB patients (n = 92), No defect (n =56) and,
defect (n = 36). Horizontal bars indicate median and interquartile range. Statistical analysis was performed using non-parametric Kruskal-Wallis
and Dunn’s multiple comparisons test, the mean rank of each column was compared with the mean rank of every other column. Comparison between
pairs of groups was not significant (P ≥ 0.05) for all data points. (C) Comparison of MPV parameters between types of platelet defects identifiedvia
lumiaggregometry. A scatter dot plot showing the spread of MPV results between the recruits. Healthy controls (n = 43), all HMB patients (n =
162), No defect (n = 86), and defect (n = 76). Horizontal bars indicate median and interquartile range. Statistical analysis performed using the non-
parametric Kruskal-Wallis test and Dunn’s adjustment for multiple comparisons, the mean rank of each column was compared with the mean rank of
every othercolumn. Statistically significant difference is denoted by * = P ≤ 0.05. (D) Comparison of ATP-secretion between types of platelet
defects identified by lumiaggregometry. Scatter dot plot showing the spread of ATP secretion results between the recruited patients. Healthy
controls (n = 42), all HMB patients (n = 155), no defect (n = 89), and defect (n = 66). Horizontal bars indicate median and interquartile range.
Statistical analysis was performed using non-parametric Kruskal-Wallis and Dunn’s multiple comparisons test, the mean rank of each column was
compared with the mean rank of every other column. Statistically significant difference is denoted by *** = P ≤ 0.001.
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more specialised laboratories. Furthermore, a recent study by
Eising et al. reported a high prevalence of reduced thrombin
generation and/or decreased platelet response in women with
unexplained heavy menstrual bleeding, implicating the need for
more specialised laboratory tests [23].
The prevalence of PFDs in our study may support the conten-
tion of other authors that platelet function testing could be incor-
porated into the investigative algorithms of women with
unexplained HMB [8,24]. The integration of these findings into
existing guidance or to inform the development of new HMB
guidelines may encourage more effective non-surgical manage-
ment with an emphasis on haemostatically orientated interven-
tions such as the use of desmopressin, inhibitors of fibrinolysis
(e.g. tranexamic acid) or platelet transfusions, in isolation or in
conjunction with recommended, evidence-based hormonal treat-
ments. In this way patient outcomes may be improved and the
rates of more morbid surgical treatments, such as hysterectomy
reduced.
Conclusion and Research Recommendations
Previously undiagnosed platelet function disorders are highly preva-
lent amongst patients with HMB of an otherwise unknown cause. The
comprehensive laboratory and clinical data obtained in this study have
highlighted the lack of difference in clinical and routine haematologi-
cal tests (full blood count) between women with a platelet function
defect and women with no identifiable platelet function defect. It is
evident that further platelet function tests are useful for detection of an
underlying PFD. The impact of recognition of a PFD amongst women
with HMB on subsequent management and clinical outcomes needs
further study. It should also be borne in mind that their identification
may also have a large impact on the management of their disorder in
non-gynaecological situations involving future haemostatic challenges
such as surgery or childbirth.
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